The BioPharmX management team consists of Silicon Valley executives, scientists and business professionals combining large company discipline with deep biotech expertise focused on drug delivery and molecular properties. The team has the proven ability to raise capital and streamline new technologies into viable, marketable and successful products.
Listed below is the senior management team at BioPharmX.
An experienced entrepreneurial pharmaceutical and med-tech C-level executive, Dr. Tierney has an extensive track record of delivering success. He has overseen the growth and successful exit of a number of specialty pharmaceutical and medical device companies. Most recently, Dr. Tierney served as president and chief executive officer of Icon Bioscience, leading his team to FDA approval of its New Drug Application (NDA) for DEXYCU™ in 2018. Dr. Tierney was president and chief operating officer of Oceana Therapeutics, a specialty therapeutic company he co-founded in 2008 and was later acquired by Salix Pharmaceuticals. In his role as president and chief executive officer of Valera Pharmaceuticals, Tierney raised over $65 million in funding and completed a successful IPO and oversaw NDA approvals of VANTAS™ and SUPPRELIN LA™. In addition to Dr. Tierney’s leadership roles, he has extensive experience in raising capital and has held a position with investment firm, Signet Health Partners. He is the recipient of two Ernst & Young Entrepreneur of the Year® awards. Dr. Tierney also serves on the board of directors of Catalyst Pharmaceuticals, Kempharm, Bimeda, and Palvella Therapeutics. Dr. Tierney received his medical degree from The Royal College of Surgeons in Dublin, Ireland.
"With a robust product pipeline and an innovative team at its core, BioPharmX is on the verge of rapid growth, transformational changes, and increased corporate visibility."
Dr. Chan is a serial biomedical entrepreneur who has developed novel, effective therapies for diverse medical conditions. His research and product development experience spans semiconductors, lasers/photonics, medical devices and biomedical sciences. He has therapeutic experience in dermatology, cardiology, urology and ophthalmology. Prior to BiopharmX, he was Vice President of Engineering at Demira where he helped develop photodynamic therapies, and directed advanced research at Solta Medical where he helped create fractional photothermolysis technology. He is a co-inventor on more than 25 patents and pending patent applications. Chan holds a Ph.D. in electrical and computer engineering from the University of Texas at Austin, where he also achieved his bachelors and masters degrees.
"BioPharmX is driven not only by a desire to explore what is possible through scientific breakthroughs but also by what science can do to satisfy the needs of patients."
Ms. Daniels is a microbiologist and biochemist by training and holds multiple patents. She has authored or contributed to dozens of peer reviewed articles and abstracts on subjects ranging from in vitro assays to breast cancer prevention. For the last 35 years she has held technical and executive level positions in start-up and development stage pharmaceutical and medical device companies working in the areas of implantable biomaterials, oncology, women’s health, pain, urology, and interventional neuroradiology. She has been responsible for all aspects of company operations and has specific expertise in design and implementation of clinical and regulatory strategy for new product development. Prior to joining BioPharmX, she led the botulinum neurotoxin program at Johnson & Johnson, the clinical research program for Boston Scientific Neuromodulation, and served as an independent consultant for a number of pharmaceutical and medical device companies.
“Being a part of a team that brings new technologies to market that change people’s lives is the most exciting way to start each day.”
A seasoned executive with decades of experience in creating license, distribution and other agreements, Ms. Bots will guide BioPharmX Corporation’s licensing and strategic partnerships. During her three-decade career, she has used licensing, partnerships and strategic acquisitions to boost the sales and profitability at several multinationals. As head of the global skincare business of Royal Philips Electronics NV, she oversaw partnership development and acquisitions, managed joint ventures with companies around the world and launched R&D programs resulting in products sold internationally. Earlier, she managed Philips’ Oral Health Care operations in EMEA leading to growth and profitability. Ms. Bots has also served in executive roles where she built, inspired and managed multi-cultural teams at Aon Risk Solutions, Reed/Elsevier, Beam Suntory, Altadis USA and Royal Agio Cigars. She has a degree in Economics from Fontys University of Applied Sciences in Eindhoven, Netherlands, and she has studied at Erasmus University in Rotterdam and Babson College in Boston.
"The right partnership and licensing agreements can help BioPharmX achieve its potential by enabling the company to more effectively focus its resources on fulfilling unmet medical needs of patients worldwide."
Dr. Herron is a physician scientist with nearly three decades of dermatology experience and maintains an active clinical practice in Palo Alto, California. As faculty at Stanford University School of Medicine he conducted biomedical research, consulted with the biopharmaceutical industry, authored or co-authored more than 30 peer-reviewed papers, and secured several patents in the biomedical field. In addition he held the position of medical director for Reliant Technologies. Dr. Herron has been honored for his work in the field and is repeatedly recognized as a thought-leading physician. He graduated from Lewis and Clark College with degrees in chemistry and biology, completed his doctoral work at Oregon State University in biochemistry and biophysics and obtained his medical doctor degree from University of Southern California Medical School.
"Dermatologists must address both physical and emotional issues because the conditions they treat often shape patients' self esteem. Our mission is to provide them more innovative therapeutic options to address some of the most common skin conditions."
Dr. Sink has a passion for capturing value from the scientific energy of small technology companies. Prior to his role at BioPharmX, Dr. Sink led the Intellectual Property Department at Reliant Technologies, a medical device company in Mountain View, CA, and held a clinical leadership role at Acclarent, a Johnson & Johnson company. He is registered to practice before the U. S. Patent and Trademark Office and is a named inventor on nine granted patents. Dr. Sink graduated from Swarthmore College where he received Bachelor of Science and Bachelor of Arts degrees and obtained both his Master of Science and Ph.D. from University of California, Santa Barbara.
"BioPharmX protects its intellectual property to create commercially viable opportunities that bring innovative products to patients."
Dr. Zayas has over 30 years of experience in operations, quality management, and research and development in antimicrobial molecules and products with an emphasis in dermatology and respiratory applications. Prior to joining BioPharmX, he headed the analytical section for GlaxoSmithKline and formulated generic injectables at Lederle Parenterals and was most recently VP of Quality Assurance and Regulatory Affairs at Ionetix Corporation. Dr. Zayas has hosted and/or participated in over 40 FDA pre-approval inspections. As founder of Zaycor Industries, a contract testing laboratory, research and development, and consulting firm, Dr. Zayas brings expertise in technology transfer, manufacturing process, stability studies and all CMC-related items to BioPharmX. Dr. Zayas has authored over a dozen publications across multiple disciplines and is the author of a patent and several pending patent applications. He holds a Ph.D. in organic chemistry from Ohio State University and completed his postdoctoral in organic chemistry from Princeton University.
"Consistently aligning internal processes with the patient in mind is at the heart of any successful operational execution."